These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8878387)

  • 21. Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.
    Capone D; Stanziale P; Gentile A; Imperatore P; Pellegrino T; Basile V
    Am J Nephrol; 1999; 19(3):411-5. PubMed ID: 10393380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increase or decrease of HDL-cholesterol concentrations during pravastatin treatment depending on the pre-treatment HDL cholesterol levels.
    Narita Y; Kitazoe Y; Kurihara Y; Okuhara Y; Takamatsu K; Saito N; Doi Y
    Eur J Clin Pharmacol; 1997; 52(6):461-3. PubMed ID: 9342581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of pravastatin on serum lipids and apolipoproteins in hyperlipidemia of the nephrotic syndrome.
    Tokoo M; Oguchi H; Terashima M; Tokunaga S; Miyasaka M; Hora K; Higuchi M; Yoshie T; Furuta S
    Nihon Jinzo Gakkai Shi; 1992 Apr; 34(4):397-403. PubMed ID: 1635284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pravastatin prevents the progression of accelerated coronary artery disease after heart transplantation in a rabbit model.
    Ogawa N; Koyama I; Shibata T; Watanabe T; Akimoto N; Taguchi Y; Shinozuka N; Omoto R
    Transpl Int; 1996; 9 Suppl 1():S226-9. PubMed ID: 8959834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
    Aliabadi AZ; Mahr S; Dunkler D; Grömmer M; Zimpfer D; Wolner E; Grimm M; Zuckermann AO
    Transplantation; 2008 Dec; 86(12):1771-6. PubMed ID: 19104420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ezetimibe is effective in the treatment of persistent hyperlipidemia of renal allograft recipients.
    Savvidaki E; Koukoulaki M; Benou A; Roumeliotou M; Fourtounas C; Kalliakmani P; Papachristou E; Vlachojannis JG; Goumenos D
    Clin Nephrol; 2011 Feb; 75(2):107-12. PubMed ID: 21255539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) Collaboration.
    Simes RJ
    Am J Cardiol; 1995 Sep; 76(9):122C-126C. PubMed ID: 7572681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia. Pravastatin and Renal Function Research Group.
    Imai Y; Suzuki H; Saito T; Tsuji I; Abe K; Saruta T
    Clin Exp Hypertens; 1999 Nov; 21(8):1345-55. PubMed ID: 10574417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile.
    Dangas G; Badimon JJ; Smith DA; Unger AH; Levine D; Shao JH; Meraj P; Fier C; Fallon JT; Ambrose JA
    J Am Coll Cardiol; 1999 Apr; 33(5):1294-304. PubMed ID: 10193730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
    Li JJ; Li YS; Chu JM; Zhang CY; Wang Y; Huang Y; Chen J; Yuan JQ; Huang YL
    Clin Chim Acta; 2006 Apr; 366(1-2):269-73. PubMed ID: 16343471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Correction of atherogenic exogenously-induced postprandial hyperlipidemia with pravastatin].
    Bubnova MG; Aronov DM; Perova NV; Olfer'ev AM; Golubev MA; Mel'kina OE; Zhasminova VG
    Kardiologiia; 2002; 42(1):27-32. PubMed ID: 12494220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of pravastatin in heart transplant recipients: implications of Kobashigawa et al.
    Gotto AM
    Curr Opin Lipidol; 1995 Dec; 6(6):341-3. PubMed ID: 8750244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
    Chikamori T; Sugimoto K; Hamada T; Kitaoka H; Furuno T; Seo H; Doi Y
    J Cardiol; 2000 Feb; 35(2):95-101. PubMed ID: 10713930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
    de Groot E; Jukema JW; van Boven AJ; Reiber JH; Zwinderman AH; Lie KI; Ackerstaff RA; Bruschke AV
    Am J Cardiol; 1995 Sep; 76(9):40C-46C. PubMed ID: 7572685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.
    Furberg CD; Pitt B; Byington RP; Park JS; McGovern ME
    Am J Cardiol; 1995 Sep; 76(9):60C-63C. PubMed ID: 7572689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia.
    Jacobson TA; Chin MM; Curry CL; Miller V; Papademetriou V; Schlant RC; LaRosa JC
    Arch Intern Med; 1995 Sep; 155(17):1900-6. PubMed ID: 7677557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a Phase IV, prospective, US, multicenter, randomized, double-blind, superiority trial.
    Sponseller CA; Morgan RE; Kryzhanovski VA; Campbell SE; Davidson MH
    Clin Ther; 2014 Aug; 36(8):1211-22. PubMed ID: 24998014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness.
    Taylor AJ; Kent SM; Flaherty PJ; Coyle LC; Markwood TT; Vernalis MN
    Circulation; 2002 Oct; 106(16):2055-60. PubMed ID: 12379573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.